Gossypetin Alleviates DSS-induced Colitis by Regulating COX2 and ROS-JNK Signaling
Rattachement africain : kr, cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Inflammatory Bowel Disease (IBD) represents a chronic and recurrent inflammatory condition affecting the gastrointestinal tract, with a rising global incidence. Current treatment approaches include surgery and drugs. However, surgeries are invasive procedures, while drug treatments often present with various side effects. Gossypetin, a flavonoid found abundantly in plants such as hibiscus, exhibits anti-oxidant and anti-cancer properties. However, its potential impact on IBD remains unexplored. OBJECTIVE: This study aimed to investigate the therapeutic potential of gossypetin on colitis. METHODS: We employed the DSS-induced colitis model to evaluate the therapeutic potential of gossypetin on colitis. The efficacy of gossypetin was assessed within this model using the Disease Activity Index (DAI) score and histological analysis. Additionally, we utilized qRT-PCR to measure the levels of inflammatory cytokines and Superoxide Dismutase (SOD). Immunohistochemistry confirmed the expression of tight junction markers, COX-2, and phosphorylated JNK protein, normally associated with disease progression. Furthermore, Western blot analysis was conducted to examine the SOD levels and anti-apoptotic effects of gossypetin. RESULTS: In DSS-induced colitis mice, gossypetin treatment ameliorated weight loss and reduced colon length caused by DSS treatment. Additionally, gossypetin-treated groups exhibited DAI scores and reduced histological damage. Moreover, gossypetin treatment increased tight junction expression, decreased inflammatory responses, reduced ROS levels, attenuated JNK signaling, and decreased apoptosis. CONCLUSION: Gossypetin shows therapeutic potential for mitigating the symptoms and progression of colitis by targeting ROS-JNK signaling involved in inflammation and tissue damage. This highlights the potential of natural compounds such as gossypetin for targeted therapies with reduced side effects and improved efficacy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Gossypetin Alleviates DSS-induced Colitis by Regulating COX2 and ROS-JNK Signaling
- Date Crossref
- 01/04/2025
- Éditeur
- Bentham Science Publishers Ltd.
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kyungpook National University Department of Animal Science and Biotechnology pays non établi dans la noticeUniversité ou école supérieure
-
National Institute of Animal Science pays non établi dans la noticeStructure de recherche
-
China-US (Henan) Hormel Cancer Institute pays non établi dans la noticeStructure de recherche
-
Hankyong National University pays non établi dans la noticeUniversité ou école supérieure
-
Daegu-Gyeongbuk Medical Innovation Foundation pays non établi dans la noticeInstitution
-
School of Life Sciences pays non établi dans la noticeUniversité ou école supérieure
-
School of Animal Life Convergence Science pays non établi dans la noticeUniversité ou école supérieure
-
Preclinical Research Center pays non établi dans la noticeStructure de recherche
Department of Animal Science and Biotechnology — Kyungpook National University, National Institute of Animal Science et China-US (Henan) Hormel Cancer Institute, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.